var data={"title":"Ethambutol: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ethambutol: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6149?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ethambutol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ethambutol: Patient drug information&quot;</a> and <a href=\"topic.htm?path=ethambutol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ethambutol: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24520118\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Myambutol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168049\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Etibi</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168087\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antitubercular Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168051\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tuberculosis, pulmonary (drug-susceptible):</b> Oral: <b>Note: </b>Always administer in combination with other antitubercular drugs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ATS/CDC/IDSA drug-susceptible tuberculosis guideline recommendations (Nahid 2016):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dosing: </i>Doses should be based on <b>lean</b> body weight for patients within a normal weight range for their height (optimal dosing for obese patients has not been established):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Once-daily therapy: <b>Note:</b> The preferred frequency of administration is once daily; however, 5-days-per-week administration by directly observed therapy (DOT) is an acceptable alternative (Nahid 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">40 to 55 kg: 800 mg (14.5 to 20 mg/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">56 to 75 kg: 1,200 mg (16 to 21.4 mg/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">76 to 90 kg: 1,600 mg (17.8 to 21.1 mg/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Three-times-weekly DOT:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">40 to 55 kg: 1,200 mg (21.8 to 30 mg/kg)</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">56 to 75 kg: 2,000 mg (26.7 to 35.7 mg/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">76 to 90 kg: 2,400 mg (26.7 to 31.6 mg/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Twice-weekly DOT:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">40 to 55 kg: 2,000 mg (36.4 to 50 mg/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">56 to 75 kg: 2,800 mg (37.3 to 50 mg/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">76 to 90 kg: 4,000 mg (44.4 to 52.6 mg/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Regimens:</i> Treatment regimens for pulmonary tuberculosis consist of an initial 2-month phase of a 4-drug regimen that includes ethambutol, followed by a continuation phase consisting of a 2-drug regimen (does not include ethambutol) of an additional 4 to 7 months; ethambutol frequency and dosing differs depending on treatment regimen selected; consult current Drug-sensitive TB guidelines (Nahid 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Tuberculous meningitis (drug-susceptible) (off-label use): </b>See Tuberculosis, pulmonary for ethambutol dose; use ethambutol as part of a 4-drug initial phase for 2 months; a 2-drug regimen (does not include ethambutol) is continued for an additional 7 to 10 months (optimal duration not defined). Adjunctive corticosteroid therapy (eg, dexamethasone, prednisolone) tapered over 6 to 8 weeks is also recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>\n        <b>Mycobacterium avium complex </b></i>\n      <b>(MAC) disease (off-label use):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Nodular/bronchiectatic disease:</i> 25 mg/kg 3 times weekly in combination with a 3-times-weekly regimen of a macrolide (azithromycin or clarithromycin) and rifampin; continue treatment until patient is culture negative on therapy for 1 year. <b>Note:</b> Not recommended for severe or previously treated pulmonary disease (ATS/IDSA [Griffith 2007]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Severe nodular/bronchiectatic or fibrocavitary disease:</i> 15 mg/kg once daily in combination with daily macrolide (azithromycin or clarithromycin) and rifamycin (rifampin or rifabutin) therapy; continue treatment until patient is culture negative on therapy for 1 year. May also consider addition of 3 times weekly amikacin or streptomycin early in therapy. (ATS/IDSA [Griffith 2007]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Disseminated disease in HIV-infected patients, treatment and chronic maintenance therapy</i>: 15 mg/kg once daily in combination with a macrolide (azithromycin or clarithromycin); may discontinue when patient has completed &ge;12 months of therapy, has no signs/symptoms of MAC disease, and has sustained (&gt;6 months) CD4 count &gt;100 cells/mm<sup>3</sup> in response to ART. <b>Note:</b> Addition of a third or fourth drug should be considered for patients with advanced immunosuppression, high mycobacterial loads, or in the absence of effective ART (HHS [OI Adult 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Nontuberculous mycobacterial disease </b>\n      <b>\n        <i>(M. kansasii)</i></b>\n      <b> (off-label use):</b> Oral: 15 mg/kg/day in combination with rifampin and isoniazid or clarithromycin for a duration to include 12 months of culture-negative sputum (ATS/IDSA [Griffith 2007]; Shitrit 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168068\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=ethambutol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ethambutol: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Mycobacterium avium </i></b> <b>(MAC), secondary prophylaxis or treatment: HIV-exposed/-infected (off-label use):</b> Oral: Infants and Children: 15 to 25 mg/kg/day once daily (maximum: 2.5 g/day) with clarithromycin (or azithromycin) with or without rifabutin (CDC, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tuberculosis, pulmonary (drug-susceptible) (excludes meningitis):</b> Oral: <b>Note:</b> Always administer in combination with other antitubercular drugs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ATS/CDC/IDSA Drug-susceptible tuberculosis guideline recommendations (Nahid 2016):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dosing: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Once-daily therapy: <b>Note: </b>The preferred frequency of administration is once daily; however, 5-days-per-week administration by directly observed therapy (DOT) is an acceptable alternative.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants, Children, and Adolescents &lt;15 years and &le;40 kg: 15 to 25 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children and Adolescents &lt;15 years and &gt;40 kg and Adolescents &ge;15 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Three-times-weekly DOT: <b>Note:</b> Although suggested dosing based on experience with twice-weekly regimen; experts suggest three-times-weekly regimens are more effective than twice-weekly DOT regimens; consult guidelines for specific information.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants, Children, and Adolescents &lt;15 years, weighing &le;40 kg: 50 mg/kg/dose administered 3 times weekly.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children and Adolescents &lt;15 years weighing &gt;40 kg or Adolescents &ge;15 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Regimens:</i> Refer to adult dosing. <b>Note: </b>As an approach to avoid ethambutol associated ocular toxicity, some clinicians use a 3-drug regimen of isoniazid, rifampin, and pyrazinamide in the initial 2 months of treatment for children who are HIV-uninfected, do not have a history of TB treatment, are living in an area of low prevalence of drug-resistant TB, and have not had exposure to individuals who are from an area of high prevalence of drug-resistant TB; however, the AAP and most experts do include ethambutol as part of the intensive-phase regimen for treatment of TB.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168052\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168053\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Manufacturer's labeling: </i>Reduce dosing as determined by serum levels (specific dosing adjustments not provided); primarily renally excreted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Alternate recommendations: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment of drug-susceptible TB (Nahid 2016): Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute: 20 to 25 mg/kg/dose 3 times weekly (do not administer daily dosing)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: 20 to 25 mg/kg/dose 3 times weekly (do not administer daily dosing); administer after dialysis if given on a dialysis day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aronoff 2007:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 10 to 50 mL/minute: Administer every 24 to 36 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;10 mL/minute: Administer every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Slightly dialyzable (5% to 20%); Administer dose postdialysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peritoneal dialysis: Dose for CrCl &lt;10 mL/minute: Administer every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Continuous arteriovenous or venovenous hemofiltration: Dose for CrCl 10 to 50 mL/minute: Administer every 24 to 36 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15881385\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168024\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myambutol: 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myambutol: 400 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg, 400 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168009\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168027\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of pulmonary tuberculosis in conjunction with other antituberculosis agents</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25725534\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Mycobacterium avium complex disease; Nontuberculous mycobacterial disease (M. kansasii); Tuberculous meningitis (drug-susceptible)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168094\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myambutol may be confused with Nembutal</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168016\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Myocarditis, pericarditis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Confusion, disorientation, dizziness, hallucination, headache, malaise, peripheral neuritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Dermatitis, erythema multiforme, exfoliative dermatitis, pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Acute gout attack, hyperuricemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, gastric distress, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Eosinophilia, leukopenia, lymphadenopathy, neutropenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Abnormal hepatic function tests, hepatitis, hepatotoxicity (possibly related to concurrent therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, anaphylactoid reaction, hypersensitivity reaction (syndrome includes cutaneous reactions, eosinophilia, and organ-specific inflammation)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Color blindness, decreased visual acuity, optic neuritis, scotoma, visual disturbance (usually reversible with discontinuation; irreversible blindness has been described)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Nephritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Pneumonitis, pulmonary infiltrates (with or without eosinophilia)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168030\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to ethambutol or any component of the formulation; optic neuritis (risk vs benefit decision); use in young children, unconscious patients, or any other patient who may be unable to discern and report visual changes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168013\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic toxicity: Has been reported, possibly due to concurrent therapy. Monitor liver function prior to and during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Optic neuritis: May cause optic neuritis (unilateral or bilateral), resulting in decreased visual acuity or other vision changes. Discontinue promptly in patients with changes in vision, color blindness, or visual defects (effects normally reversible, but reversal may require up to a year). Irreversible blindness has been reported. Monitor visual acuity prior to and during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ocular disease: Evaluation of visual acuity changes may be more difficult in patients with cataracts, optic neuritis, diabetic retinopathy, and inflammatory conditions of the eye; consideration should be given to whether or not visual changes are related to disease progression or effects of therapy. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage modification recommended. Monitor renal function prior to and during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: Use only in children whose visual acuity can accurately be determined and monitored (not recommended for use in children &lt;13 years of age unless the benefit outweighs the risk).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299290\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168018\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9430&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aluminum Hydroxide: May decrease the serum concentration of Ethambutol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168020\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168033\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Ophthalmic abnormalities have been reported in infants born to women receiving ethambutol as a component of antituberculous therapy. Due to the risk of untreated tuberculosis to the mother and fetus, treatment is recommended when the probability of maternal disease is moderate to high. Ethambutol is one of the recommended agents to treat tuberculosis in pregnant women (Nahid 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168034\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Ethambutol is present in breast milk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The amount of drug in breast milk is considered insufficient for the treatment of tuberculosis in breastfed infants. Although exposure to the infant is expected to be low and not produce toxicity, some sources recommend monitoring the breastfeeding infant for rash, malaise, nausea, or vomiting (Nahid 2016; Tran 1998).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The manufacturer suggests use during breastfeeding only if benefits to the mother outweigh the possible risk to the infant. In the treatment of drug-susceptible tuberculosis, use of ethambutol is not a contraindication to breastfeeding in women deemed noninfectious and who are treated with first-line agents (ie, ethambutol) (Nahid 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168035\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May be taken with food as absorption is not affected, may cause gastric irritation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168022\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Baseline and periodic (monthly) visual testing (Snellen test) and color discrimination tests (each eye individually, as well as both eyes tested together) in patients receiving &gt;15 mg/kg/day; baseline and periodic renal, hepatic, and hematopoietic tests</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168012\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits arabinosyl transferase resulting in impaired mycobacterial cell wall synthesis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168029\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: ~80%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely throughout body; concentrated in kidneys, lungs, saliva, and red blood cells</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CSF:blood level ratio: Normal meninges: 0%; Inflamed meninges: 25%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 20% to 30%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic (20%) to inactive metabolite</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 2.5 to 3.6 hours; End-stage renal disease: 7 to 15 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 2 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~50% as unchanged drug, 8% to 15% as metabolites); feces (~20% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168032\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ethambutol HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $52.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (100): $156.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Myambutol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $57.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (100): $93.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168036\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Afimocil (KW, QA);</li>\n      <li>Ambutol (MY);</li>\n      <li>Amiobutols (LV);</li>\n      <li>Arbutol (ID);</li>\n      <li>Bacbutol (ID);</li>\n      <li>Clobutol (PT);</li>\n      <li>Combutol (IN);</li>\n      <li>Dexambutol (FR);</li>\n      <li>E-Butol (SG);</li>\n      <li>Ebutol (SG, TW);</li>\n      <li>Ecox (CO, ET, LK, MY);</li>\n      <li>Ekoks (UA);</li>\n      <li>EMB (DE);</li>\n      <li>EMB-Fatol (HK);</li>\n      <li>Etambutol (BG, HR);</li>\n      <li>Etambutol Northia (AR);</li>\n      <li>Etambutol Richet (AR);</li>\n      <li>Etambutol Richmond (AR);</li>\n      <li>Etapiam (IT);</li>\n      <li>ETH Ciba 400 (ID);</li>\n      <li>Etham (BD, TH);</li>\n      <li>Ethambin-PIN (PH);</li>\n      <li>Ethambutol (PL);</li>\n      <li>Ethbutol (TH);</li>\n      <li>Etibi (AT, ID, IT);</li>\n      <li>Eubotol (VN);</li>\n      <li>Inbutol (UA);</li>\n      <li>Interbutol (PH);</li>\n      <li>Kombutol (UA);</li>\n      <li>Lambutol (TH);</li>\n      <li>Litamol (VN);</li>\n      <li>Manzida (MX);</li>\n      <li>Myambutol (AE, AT, AU, BB, BE, BF, BJ, CH, CI, DE, DK, ES, ET, FR, GB, GH, GM, GN, GR, IN, KE, KR, KW, LR, LU, MA, ML, MR, MU, MW, MY, NE, NG, NL, NZ, PK, PT, QA, SA, SC, SD, SE, SI, SL, SN, TH, TN, TZ, UG, ZM, ZW);</li>\n      <li>Mycobac (BD);</li>\n      <li>Mycobutol (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Oributol (FI);</li>\n      <li>Purderal (ZA);</li>\n      <li>Riotol (TW);</li>\n      <li>Servambutol (PE);</li>\n      <li>Stambutol (FI);</li>\n      <li>Sural (BD, CZ, HN, HU);</li>\n      <li>Tambutol (KR);</li>\n      <li>Thamtol (ET);</li>\n      <li>Thural (BD);</li>\n      <li>Tibigon (ID);</li>\n      <li>Tibitol (ID, IN);</li>\n      <li>Tibutol (PE);</li>\n      <li>Tobutol (TH);</li>\n      <li>Winbutol (TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Addis A, Blowey D, and Koren G, &ldquo;Tuberculosis During Pregnancy,&rdquo; <i>Can Fam Physician</i>, 1996, 42:1461-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethambutol-drug-information/abstract-text/8792014/pubmed\" target=\"_blank\" id=\"8792014\">8792014</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics, Committee on Infectious Diseases, &ldquo;Chemotherapy for Tuberculosis in Infants and Children,&rdquo; <i>Pediatrics</i>, 1992, 89(1):161-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethambutol-drug-information/abstract-text/1728006/pubmed\" target=\"_blank\" id=\"1728006\">1728006</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Thoracic Society, &ldquo;Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection,&rdquo; <i>MMWR Recomm Rep</i>, 2000, 49(RR-6):1-51.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8016763\"></a>British Thoracic Society. <i>Mycobacterium kansasii </i>pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society. <i>Thorax</i>. 1994;49(5):442-445.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethambutol-drug-information/abstract-text/8016763/pubmed\" target=\"_blank\" id=\"8016763\">8016763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention, &ldquo;Treatment of Tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America,&rdquo; 2003,&rdquo; <i>MMWR Recomm Rep</i>, 52(RR11):3-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethambutol-drug-information/abstract-text/12836625/pubmed\" target=\"_blank\" id=\"12836625\">12836625</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ducobu J, DuPont P, Laurent M, et al, &ldquo;Acute Isoniazid/Ethambutol/Rifampicin Overdosage,&rdquo; <i>Lancet</i>, 1982, 1(8272):632.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griffith DE, Aksamit T, Brown-Elliott BA, et al, &ldquo;An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases,&rdquo; <i>Am J Respir Crit Care Med</i>, 2007, 175(4):367-416.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethambutol-drug-information/abstract-text/17277290/pubmed\" target=\"_blank\" id=\"17277290\">17277290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14557961\"></a>Griffith DE, Brown-Elliott BA, Wallace RJ Jr. Thrice-weekly clarithromycin-containing regimen for treatment of <i>Mycobacterium kansasii</i> lung disease: results of a preliminary study. <i>Clin Infect Dis</i>. 2003;37(9):1178-1182.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethambutol-drug-information/abstract-text/14557961/pubmed\" target=\"_blank\" id=\"14557961\">14557961</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Havlir DV and Barnes PF, &ldquo;Tuberculosis in Patients With Human Immunodeficiency Virus Infection,&rdquo; <i>N Engl J Med</i>, 1999, 340(5):367-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethambutol-drug-information/abstract-text/9929528/pubmed\" target=\"_blank\" id=\"9929528\">9929528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. <i>Clin Infect Dis</i>. 2016;63(7):e147-e195. doi: 10.1093/cid/ciw376<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethambutol-drug-information/abstract-text/27516382/pubmed\" target=\"_blank\" id=\"27516382\">27516382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Prevention and Treatment of Tuberculosis Among Patients Infected With Human Immunodeficiency Virus: Principles of Therapy and Revised Recommendations. Centers for Disease Control and Prevention,&rdquo; <i>MMWR Recomm Rep</i>, 1998, 47(RR-20):1-58.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16537880\"></a>Shitrit D, Baum GL, Priess R, et al. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome. <i>Chest</i>. 2006;129(3):771-776.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethambutol-drug-information/abstract-text/16537880/pubmed\" target=\"_blank\" id=\"16537880\">16537880</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Starke JR, &ldquo;Multidrug Therapy for Tuberculosis in Children,&rdquo; <i>Pediatr Infect Dis J</i>, 1990, 9(11):785-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethambutol-drug-information/abstract-text/2124671/pubmed\" target=\"_blank\" id=\"2124671\">2124671</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Starke JR and Correa AG, &ldquo;Management of Mycobacterial Infection and Disease in Children,&rdquo; <i>Pediatr Infect Dis J</i>, 1995, 14(6):455-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethambutol-drug-information/abstract-text/7667049/pubmed\" target=\"_blank\" id=\"7667049\">7667049</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tran JH and Montakantikul P, &ldquo;The Safety of Antituberculosis Medications During Breastfeeding,&rdquo; <i>J Hum Lact</i>, 1998, 14(4):337-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethambutol-drug-information/abstract-text/10205455/pubmed\" target=\"_blank\" id=\"10205455\">10205455</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Treatment of Latent Tuberculosis Infection (LTBI), Last Updated: April 8, 2004.&rdquo; Available at <a href=\"http://www.cdc.gov/nchstp/tb/pubs/tbfactsheets/250110.htm\" target=\"_blank\">http://www.cdc.gov/nchstp/tb/pubs/tbfactsheets/250110.htm</a>. Last accessed February 16, 2005.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed July 12, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yoshikawa TT, &ldquo;Tuberculosis in Aging Adults,&rdquo; <i>J Am Geriatr Soc</i>, 1992, 40(2):178-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethambutol-drug-information/abstract-text/1740604/pubmed\" target=\"_blank\" id=\"1740604\">1740604</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9430 Version 135.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F24520118\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F168049\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F168087\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F168051\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F168068\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F168052\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F168053\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15881385\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F168024\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F168009\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F168027\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25725534\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F168094\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F168016\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F168030\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F168013\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299290\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F168018\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F168020\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F168033\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F168034\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F168035\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F168022\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F168012\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F168029\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F168032\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F168036\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9430|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ethambutol-patient-drug-information\" class=\"drug drug_patient\">Ethambutol: Patient drug information</a></li><li><a href=\"topic.htm?path=ethambutol-pediatric-drug-information\" class=\"drug drug_pediatric\">Ethambutol: Pediatric drug information</a></li></ul></div></div>","javascript":null}